Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AbbVie Inc.
Sierra announced Phase III results for the JAK inhibitor in anemic myelofibrosis patients with previous JAK exposure, a difficult-to-treat population. Trial investigator Ruben Mesa talked to Scrip about some of the advantages.
In this roundup feature focusing on new developments in digital health, Medtech Insight spotlights the push behind digital therapeutics, Abbott’s biowearable line, Exec Chats with iRhythm and Cognetivity, Right To Repair rules for tech, and FDA's guidance on 3D-printing.
The company kicked off the new year with a new CEO, plans to break out consumer health, and a strong financial position, including $32bn in cash and lowest level of net debt in more than four years.
Few drug patent infringement cases go to court in China, where a murky and lengthy process deters many from pursuing litigation. But a newly enacted Patent Law with patent linkage provisions is spurring a rise in infringement lawsuits, with one recent case involving a major Japanese pharma firm underscoring the remaining challenges.
- Other Names / Subsidiaries
- Pharmacyclics, Inc.
- Stemcentrx, Inc.